TAFALGIE The first in-class non-opioid drug for treating moderate, severe, and persistent pain with no addiction nor tolerance
- Coordinator
- Tafalgie Therapeutics, France
- Runs
- 1 March 2024 to 30 November 2026
- Status
- Running
- EU funding
- €2.5m
- Total cost
- €17.4m
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101145380
What the project is doing
In the project's own words, from its summary on CORDIS.
Tafalgie Therapeutics is a biopharmaceutical research company developing a new scientific approach for next-generation treatments, based on a true breakthrough innovation derived from the mechanism of action of an endogenous protein modulating the pain signal. Our ambition: to become the reference player in the field of pain medication by designing and proposing new active pharmaceutical ingredients for non-opioid analgesics, in a context marked by the opioid crisis, through the development of first-in-class polypeptides derived from TAFA4 and its peptide derivatives.
We aim to develop and bring to patients more effective, well-tolerated, non-addictive, long-term treatments for the relief of acute pain - mild, moderate, and severe -, as well as for the prevention of chronic pain.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Tafalgie Therapeutics | Marseille | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI